Real-world adjuvant TAC or FEC-D for HER2-negative node-positive breast cancer in women less than 50 years of age.

about

Value of the level of methylation of RASSF1A and WIF-1 in tissue and serum in neoadjuvant chemotherapeutic assessment for advanced breast cancer.

P2860

Q41389445-4BACC97D-6678-40C1-BA3C-61A26C20247F

P2860

Real-world adjuvant TAC or FEC-D for HER2-negative node-positive breast cancer in women less than 50 years of age.

Item

http://www.wikidata.org/entity/Q36989067

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Real-world adjuvant TAC or FEC ...... men less than 50 years of age.

@en

type

Item

label

Real-world adjuvant TAC or FEC ...... men less than 50 years of age.

@en

prefLabel

Real-world adjuvant TAC or FEC ...... men less than 50 years of age.

@en

P1476

Real-world adjuvant TAC or FEC ...... men less than 50 years of age.

@en

P2093

A A Joy

http://www.w3.org/2001/XMLSchema#string

D Tilley

http://www.w3.org/2001/XMLSchema#string

S Lupichuk

http://www.w3.org/2001/XMLSchema#string

X Kostaras

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2015

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial.

Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer.

Combination chemotherapy as an adjuvant treatment in operable breast cancer.

Risk of hospitalization according to chemotherapy regimen in early-stage breast cancer.

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update.

Real-world experience with adjuvant fec-d chemotherapy in four Ontario regional cancer centres

Innovations in the Ethical Review of Health-Related Quality Improvement and Research: The Alberta Research Ethics Community Consensus Initiative (ARECCI).

P304

164-170

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3747/CO.23.3004

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-06-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27330344

http://www.w3.org/2001/XMLSchema#string

P932

4900827

http://www.w3.org/2001/XMLSchema#string

Real-world adjuvant TAC or FEC-D for HER2-negative node-positive breast cancer in women less than 50 years of age.

about

P2860

P2860

Real-world adjuvant TAC or FEC-D for HER2-negative node-positive breast cancer in women less than 50 years of age.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932